VALPROATE        SUPPORTING DATA 
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Guidelines

Strengths:

Established efficacy in acute mania

  • The acute and prophylactic response with valproate was most notable in patients with mania and mixed states. [ICG Guidelines]
  • Valproate should be considered as add-on therapy in breakthrough mania because it has proven efficacy in mania. [ICG Guidelines]

Weaknesses:

Evidence supporting valproate as bipolar maintenance therapy is limited and inconsistent

  • While unlikely to provoke a manic switch, lithium, valproate, and carbamazepine have inadequate evidence for efficacy as acute antidepressants. [BAP Guidelines]

Side effects including somnolence, weight gain, and endocrine changes

  • Valproate, lithium, and several antipsychotics all cause significant weight gain in patients with long-term treatment. Weight gain is associated with other adverse metabolic effects (e.g. carbohydrate intolerance/type II diabetes and hyperlipidemia) and hypertension. [WFSBP Guidelines]
British Association for Psychopharmacology
International Consensus Group on Bipolar I Depression
International Consensus Group on Bipolar I Depression
World Federation of Societies of Biological Psychiatry
World Federation of Societies of Biological Psychiatry
World Federation of Societies of Biological Psychiatry
World Federation of Societies of Biological Psychiatry


 
  
home help sitemap acronyms help sitemap home